Cargando…

Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes

BACKGROUND: First-line therapy for treatment of advanced urothelial carcinoma includes combination platinum-based chemotherapies, though resistance and long-term toxicity concerns to these regimens cause limitations in progression-free survival and overall survival. Maintenance treatment with an alt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ten Eyck, Jennifer E, Kahlon, Navkirat, Masih, Sonia, Hamouda, Danae M, Petros, Firas G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882657/ https://www.ncbi.nlm.nih.gov/pubmed/35237074 http://dx.doi.org/10.2147/CMAR.S227323

Ejemplares similares

The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape
por: Koshkin, Vadim S., et al.
Publicado: (2019)

Post-cardiac Arrest Leukocytosis Mimicking Acute Monocytic Leukemia
por: Kahlon, Navkirat, et al.
Publicado: (2022)

Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019
por: Kahlon, Navkirat, et al.
Publicado: (2022)

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
por: Grivas, P., et al.
Publicado: (2023)

Improving Outcomes for Patients With Advanced Urothelial Carcinoma
por: Grivas, Petros, et al.
Publicado: (2020)

Risk Factors Associated With Six-Month Mortality in Hospitalized COVID-19 Patients: A Single-Institution Study
por: Kahlon, Navkirat, et al.
Publicado: (2022)

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
por: Powles, Thomas, et al.
Publicado: (2023)

Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma
por: Novakovic, Ana M., et al.
Publicado: (2019)

Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma
por: Wilkins, Justin J., et al.
Publicado: (2019)

Epidemiology, clinical presentation, and evaluation of upper-tract urothelial carcinoma
por: Petros, Firas G.
Publicado: (2020)

Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region
por: Eto, Masatoshi, et al.
Publicado: (2022)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
por: Xie, Qian, et al.
Publicado: (2022)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma
por: Xie, Qian, et al.
Publicado: (2022)

Acanthosis Nigricans in a Patient with Urothelial Carcinoma Treated with PD-L1 Inhibitor Avelumab, and Secondary Adrenal Insufficiency
por: Lai, Fei Ya, et al.
Publicado: (2023)

Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
por: Levy, Sonja, et al.
Publicado: (2020)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
por: Strauss, Julius, et al.
Publicado: (2023)

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
por: Tomita, Yoshihiko, et al.
Publicado: (2022)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2022)

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
por: Coquan, Elodie, et al.
Publicado: (2022)

A review of avelumab in locally advanced and metastatic bladder cancer
por: Rao, Arpit, et al.
Publicado: (2019)

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
por: Kongnakorn, Thitima, et al.
Publicado: (2019)

Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival
por: Lohray, Rishabh, et al.
Publicado: (2023)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Re-Induction of Avelumab for Patients with Metastatic Merkel Cell Carcinoma
por: Hiroyuki, Goto, et al.
Publicado: (2023)

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
por: Apolo, Andrea B., et al.
Publicado: (2017)

Elevated International Normalized Ratio Due to Apixaban in Patient With End-Stage Renal Disease on Hemodialysis
por: Kahlon, Navkirat, et al.
Publicado: (2022)

Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors
por: Vugmeyster, Yulia, et al.
Publicado: (2022)

Current status of the focused series “Urothelial Carcinoma”
por: Yuk, Hyeong Dong, et al.
Publicado: (2020)

A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
por: Su, Po‐Jung, et al.
Publicado: (2023)

Plasmacytoid variant of urothelial carcinoma of the bladder manifesting as bilateral ureteral and small bowel obstruction
por: Carsel, Alex, et al.
Publicado: (2020)

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
por: Lanitis, Tereza, et al.
Publicado: (2019)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
por: Tiako Meyo, Manuela, et al.
Publicado: (2022)

Avelumab in metastatic collecting duct carcinoma of the kidney: a case report
por: Pyrgidis, Nikolaos, et al.
Publicado: (2023)

Evaluation of the potential for QTc prolongation with avelumab
por: Vugmeyster, Yulia, et al.
Publicado: (2019)

Favorable Response to Treatment with Avelumab in an HIV-Positive Patient with Advanced Merkel Cell Carcinoma Previously Refractory to Chemotherapy
por: Al Homsi, Mohammed U., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ejo1f8ikr4v08dmom96cf1g9qu